Long-term treatment of ghrelin stimulates feeding, fat deposition, and alters the GH/IGF-I axis in the tilapia, Oreochromis mossambicus

被引:90
|
作者
Riley, LG [1 ]
Fox, BK
Kaiya, H
Hirano, T
Grau, EG
机构
[1] Univ Hawaii, Hawaii Inst Marine Biol, Kaneohe, HI 96744 USA
[2] Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Suita, Osaka 5658565, Japan
关键词
ghrelin; feeding; fat metabolism; GH/IGF-I axis; tilapia;
D O I
10.1016/j.ygcen.2005.01.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently, a new peptide, ghrelin, which specifically stimulates growth hormone (GH) release from the pituitary, was identified in the rat and human stomach. Ghrelin has been Shown to stimulate GH release by acting through a growth hormone secretagogue receptor. We have identified two ghrelins (ghrelin-C8 and -C10) in the stomach of tilapia, a euryhaline fish. The current Study was aimed at investigating the in vivo effect of the two tilapia ghrelins on feeding, fat deposition, and on the GH/IGF-I axis. Tilapia were implanted with micro-osmotic pumps containing either ghrelin-C8, ghrelin-C10 or saline (control). Ghrelin was delivered at a continuous rate of 10 ng/h for 21 days. Food consumption increased significantly in those animals that received ghrelin-C10 but not ghrelin-C8. Treatment with ghrelin-C10 increased body weight significantly without altering body length. Hence, the condition factor was significantly higher in the ghrelin-C 10 group compared with the control. Liver weight and total fat content in the liver were also elevated significantly in the fish treated with ghrelin-C10. There was no effect of either ghrelin on plasma GH levels, whereas plasma IGF-I levels were reduced significantly in the ghrelin-C10 group. These findings demonstrate that ghrelin plays a role in feeding and fat metabolism in the tilapia, and Suggest that the two forms of ghrelin may be acting through different receptors. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:234 / 240
页数:7
相关论文
共 43 条
  • [21] Effect of GH/IGF-I deficiency on long-term renal changes and urinary albumin excretion in diabetic dwarf rats
    Gronbaek, H
    Volmers, P
    Bjorn, SF
    Osterby, R
    Orskov, H
    Flyvbjerg, A
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1997, 272 (05): : E918 - E924
  • [22] Uremia results in impaired induction of liver IGF-I mRNA and GH receptor mRNA even after long-term rhGH treatment.
    Hisano, S
    Chan, W
    Latta, K
    Krieg, R
    Chan, JCM
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A3043 - A3043
  • [23] Long-term treatment of growth hormone insensitivity syndrome with IGF-I - Results of the European multicentre study
    Ranke, MB
    Savage, MO
    Chatelain, PG
    Preece, MA
    Rosenfeld, RG
    Wilton, P
    HORMONE RESEARCH, 1999, 51 (03) : 128 - 134
  • [24] Benefits of Recombinant Adeno-Associated Virus (rAAV)-Mediated Insulinlike Growth Factor I (IGF-I) Overexpression for the Long-Term Reconstruction of Human Osteoarthritic Cartilage by Modulation of the IGF-I Axis
    Weimer, Anja
    Madry, Henning
    Venkatesan, Jagadeesh K.
    Schmitt, Gertrud
    Frisch, Janina
    Wezel, Anna
    Jung, Jochen
    Kohn, Dieter
    Terwilliger, Ernest F.
    Trippel, Stephen B.
    Cucchiarini, Magali
    MOLECULAR MEDICINE, 2012, 18 (03) : 346 - 358
  • [25] Benefits of Recombinant Adeno-Associated Virus (rAAV)-Mediated Insulinlike Growth Factor I (IGF-I) Overexpression for the Long-Term Reconstruction of Human Osteoarthritic Cartilage by Modulation of the IGF-I Axis
    Anja Weimer
    Henning Madry
    Jagadeesh K. Venkatesan
    Gertrud Schmitt
    Janina Frisch
    Anna Wezel
    Jochen Jung
    Dieter Kohn
    Ernest F Terwilliger
    Stephen B. Trippel
    Magali Cucchiarini
    Molecular Medicine, 2012, 18 : 346 - 358
  • [26] Short- and Long-Term Efficacy of Combined Cabergoline and Octreotide Treatment in Controlling IGF-I Levels in Acromegaly
    Mattar, Priscilla
    Alves Martins, Manoel Ricardo
    Abucham, Julio
    NEUROENDOCRINOLOGY, 2010, 92 (02) : 120 - 127
  • [27] Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors
    C. L. Ronchi
    M. Peracchi
    S. Corbetta
    S. Massironi
    C. Ciafardini
    D. Conte
    P. Beck-Peccoz
    A. Spada
    Journal of Endocrinological Investigation, 2007, 30 : 241 - 246
  • [28] Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors
    Ronchi, C. L.
    Peracchi, M.
    Corbetta, S.
    Massironi, S.
    Ciafardini, C.
    Conte, D.
    Beck-Peccoz, P.
    Spada, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2007, 30 (03) : 241 - 246
  • [29] Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment
    Bannink, Ellen M. N.
    Van Doorn, Jaap
    Stijnen, Theo
    Drop, Stenvert L. S.
    Keizer-Schrama, Sabine M. P. F. de Muinck
    CLINICAL ENDOCRINOLOGY, 2006, 65 (03) : 310 - 319
  • [30] Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity
    Chernausek, Steven D.
    Backeljauw, Philippe F.
    Frane, James
    Kuntze, Joyce
    Underwood, Louis E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (03): : 902 - 910